Long-Term Medications Associated with Thiamine Deficiency
Chronic diuretic therapy, particularly loop diuretics like furosemide, is the primary long-term medication associated with thiamine deficiency, with supplementation of 50 mg daily recommended for patients on chronic diuretic therapy 1.
Primary Medication: Loop Diuretics
Loop diuretics (furosemide, torasemide) cause thiamine deficiency through increased urinary thiamine losses proportional to urinary flow rate and may directly inhibit cellular thiamine uptake 2, 3. The 2022 ESPEN Micronutrient Guideline specifically identifies chronic diuretic therapy as a risk factor requiring increased gastrointestinal or renal losses monitoring 1. Recent pharmacovigilance data from 2004-2024 identified furosemide as the most frequently reported medication associated with thiamine deficiency adverse events, with hospitalization occurring in 46% of cases 4.
Clinical Significance
- Thiamine deficiency in heart failure patients on diuretics is found in approximately 6% of ambulatory patients 1
- The deficiency can contribute to worsening cardiac function, creating a vicious cycle in heart failure management 2, 5
- Furosemide dosage shows a dose-dependent association with thiamine status changes 6
Other Medications with Safety Signals
Thiazide Diuretics
Hydrochlorothiazide and chlorthalidone also demonstrate safety signals for thiamine deficiency, though the evidence primarily focuses on potassium and magnesium depletion 7, 4. These agents work through similar mechanisms of increased urinary losses.
Metformin
While the 2021 Annual Review of Nutrition discusses metformin extensively, it specifically addresses vitamin B12 deficiency, not thiamine deficiency 7. This medication should not be confused with thiamine-depleting agents.
Additional Agents from Pharmacovigilance Data
The 2026 pharmacovigilance study identified 38 drugs with consistently positive safety signals across all detection methods 4:
- Metronidazole (antibiotic)
- Fluorouracil (chemotherapy)
- Fedratinib (JAK2 inhibitor)
- Arsenic trioxide (chemotherapy)
- Rabeprazole (proton pump inhibitor)
These agents likely cause deficiency through mechanisms including transport inhibition and metabolic interference 4.
Clinical Algorithm for Management
Risk Assessment
Monitor thiamine status in patients with:
- Chronic diuretic therapy (especially furosemide at any dose)
- Cardiomyopathy with prolonged diuretic treatment 1
- Multiple risk factors: elderly, malnourished, alcoholic patients on diuretics 5
Supplementation Strategy
For patients on chronic diuretic therapy without clinical deficiency:
- 50 mg thiamine daily by mouth 1
For patients with proven or suspected deficiency:
- 200 mg three times daily IV for high suspicion or proven deficiency 1
- Maintenance: 50-100 mg/day orally after repletion 1
Important Caveats
- Thiamine reserves deplete within 20 days of inadequate intake 1, making early recognition critical
- The deficiency can cause irreversible neurological damage (Wernicke-Korsakoff encephalopathy) if untreated 1
- Do not delay treatment while awaiting laboratory confirmation—initiate supplementation based on clinical suspicion 1
- Higher doses (exceeding 50 mg/day) may be necessary in patients with documented deficiency on diuretics 6
Monitoring
Measure RBC or whole blood thiamine diphosphate (ThDP) in:
- Patients with cardiomyopathy on prolonged diuretic treatment 1
- Any patient on chronic diuretics with unexplained neurological symptoms or worsening heart failure
The convergence of guideline recommendations and recent pharmacovigilance data strongly supports routine thiamine supplementation in all patients requiring chronic diuretic therapy, particularly those on loop diuretics.